Poor
Poorly Aligned
Patient Risk:
Moderate
Summary
The supplied label supports hypertension treatment with the lisinopril/hydrochlorothiazide combination and describes lisinopril's ACE-inhibiting mechanism. It does not substantiate the extensive ibuprofen interaction claims, specific risks, dosing advice, timelines, or monitoring instructions in the extracted claims.
Category Scores
Accurate Statements
The lisinopril/hydrochlorothiazide combination is indicated for hypertension.
Indications and Usage identifies the fixed-dose combination for treatment of hypertension.
Lisinopril inhibits ACE, reducing angiotensin II and its vasopressor activity.
Clinical Pharmacology—Mechanism of Action describes ACE inhibition, decreased plasma angiotensin II, and decreased vasopressor activity.
Older patients may have decreased renal function, and renal function should be assessed in evaluating a hypertensive patient.
Geriatric Use notes the greater frequency of decreased renal function in older patients and says evaluation of the hypertensive patient should include assessment of renal function. This does not establish the claimed ibuprofen-specific risk.
Fatigue and nausea are listed adverse experiences with lisinopril/hydrochlorothiazide.
Adverse Reactions lists fatigue and nausea; it does not identify them as signs of kidney effects from combining lisinopril and ibuprofen.
Unsupported Statements
The claims that ibuprofen is an NSAID pain reliever and that it has a moderate interaction with lisinopril.
The supplied label sections do not discuss ibuprofen or characterize an interaction with it.
Claims that ibuprofen affects potassium excretion, renal blood flow, prostaglandins, or lisinopril's blood-pressure effect, and that the combination causes acute kidney injury or kidney failure.
These interaction mechanisms and outcomes are not described in the supplied label sections.
Claims about dehydration, age, kidney disease, diabetes, heart failure, diuretics, low-salt diets, or ibuprofen dose thresholds increasing the interaction risk.
The supplied label discusses renal impairment and geriatric use generally, but does not establish these factors as risks from combining lisinopril and ibuprofen.
Claims about a 20–30% or greater GFR reduction, creatinine or potassium increases from the combination, related symptoms, or effects beginning within days.
The supplied label provides no such interaction-specific measurements, symptoms, or timing.
Claims that effects reverse within 1–2 weeks, that permanent damage occurs in 1–5% of severe cases, or that occasional low-dose ibuprofen is comparatively lower risk.
The supplied label does not report these outcomes, frequencies, timelines, or dose comparisons.
Recommendations to avoid routine combined use, substitute acetaminophen, use the lowest effective ibuprofen dose for the shortest time, or adjust lisinopril during combined use.
The supplied label sections do not provide these recommendations.
Recommendation to monitor kidney function before and during combined lisinopril and ibuprofen use.
The label supports renal-function assessment in evaluation of hypertensive patients, but does not specify this interaction-specific monitoring schedule.
Lisinopril is indicated for heart failure.
Heart failure is not identified as an indication in the supplied lisinopril/hydrochlorothiazide label sections.
Lisinopril relaxes blood vessels by blocking angiotensin II.
The label describes lisinopril as inhibiting ACE and reducing angiotensin II; it does not say lisinopril directly blocks angiotensin II.
Contradictions
Important Omissions
Clarify that the supplied indication applies to the fixed-dose lisinopril/hydrochlorothiazide product; the provided sections do not establish all indications for lisinopril alone.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The claims give interaction-specific risk estimates, timelines, and medication recommendations that are not supported by the supplied label sections. The available information does not establish those claims as label instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Poorly Aligned
Primary Issue
Most ibuprofen interaction claims and specific clinical details are not supported by the supplied prescribing information.
Suggested Improvement
Limit claims to the supplied label text, distinguish the lisinopril/hydrochlorothiazide product from lisinopril alone, and avoid presenting interaction-specific risks or recommendations as label-supported.